2024 年第一季度报告 证券代码：688192 证券简称：迪哲医药 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 第一季度财务报表是否经审计 一、 主要财务数据 本报告期比上年 2024 年第一季度报告 (二)非经常性损益项目和金额 2024 年第一季度报告 (三)主要会计数据、财务指标发生变动的情况、原因 二、 股东信息 3 / 13 4 / 13 | --- | --- | --- | --- | --- | |------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------ ...

迪哲（江苏）医药股份有限公司 2023 年年度报告 重要提示 一、 本公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实性、准确性、 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 公司上市时未盈利且尚未实现盈利 √是 □否 公司是一家全球创新型生物医药企业，专注于恶性肿瘤和自身免疫性疾病领域创新药的研究、 开发及商业化，采用科创板第五套标准上市。2023 年 8 月，公司首个商业化产品舒沃哲®（通用 名：舒沃替尼片）中国获批上市，报告期内舒沃哲®实现销售收入 9,128.86 万元。此外，2023 年 9 月中国药品监督管理局（NMPA）受理了戈利昔替尼的新药上市申请（NDA）并纳入优先审评程 序。截至 2023 年 12 月 31 日，公司尚未盈利且存在累计未弥补亏损。报告期内，公司持续投入资 金用于推进注册临床试验，研发费用投入增大；同时，为产品上市扩大销售团队并加大推广力度， 公司运营费用有所增加。 三、 重大风险提示 公司已在本年度报告详细阐述在生产经营过程中可能面临的各种风险因素，敬请参阅"第三 节 管理层讨论与分析"之"四、风险因素"相关内容。 ...

公 司 研 究 证券研究报告 ＃industryId＃ 化学制剂 ＃investSuggestion＃ 增持 ( ＃ investSug gestionCh ange＃ 维持 ） ＃dyCompany＃ 迪哲医药 （688192.SH ） 000009 ＃title＃ 舒沃替尼销售符合预期，差异化管线进展顺利 ＃createTime1＃ 2024 年 02 月 26 日 投资要点 ＃summary＃ ⚫ 事件：公司发布 2023 年业绩快报，2023 年实现营业收入 0.91 亿元（2022 年无收入），均为舒沃替尼销售收入，实现归母净利润-11.23 亿元（2022 年同期为-7.36 亿元），实现扣非归母净利润-11.77 亿元（2022 年同期为7.85 亿元）。 ⚫ 点评：舒沃替尼销售启航符合预期，临床数据持续展现差异化，全球进展 顺利。戈利昔替尼全球注册临床数据亮眼，国内 NDA 并获得优先审评资 格，海外进展可期，维持治疗初步数据提供进入前线的可能性。FIC 药物 DZD8586 靶点公开，ASH 数据展示出在 DLBCL 以及 BTK 耐药方面的 治疗潜质。研发费用保持增长，回购展现管理层长期信 ...

每经编辑 叶峰 创新药盘中反攻，迪哲医药涨14%，万泰生物、药明生物、九洲药业、神州细胞等多股上涨，创新药沪 深港ETF（517110）涨4%。 供给端来看，近年来我国创新药在数量和质量上都实现了跨越，行业逐步进入创新主导的阶段。去年是 创新药出海大年，全年向海外授权的金额创下历史新高，叠加在疾病领域和新技术平台的研发突破，行 情有望得到催化。 需求端上，人口老龄化带来的诊疗需求增长确定性较高，对行业的持续发展有较强的支撑。政策面上， 集采和反腐的短期利空已基本被市场定价消化，且中长期来看利好行业发展。 消息面和公司治理上，自上月29日沪指失守2900点以来，据不完全统计，已有超过百家医药行业的公司 发布回购相关公告，维护公司股价的稳定，践行“以投资者为本”的上市公司发展理念，切实“提质增效 重回报”。其中，（拟）进行回购的公司包括药明康德、凯莱英（CXO）、海翔药业（原料药）等行业 或细分领域的头部企业。多家公司都提到市场下跌后的股价未能有效反映公司实际投资价值和经营业 绩，公司拟以回购行为增加投资者信心，并促进公司股票价格合理回归内在价值。 没有股票账户的投资者可以通过创新药沪深港ETF的联接基金（014 ...

证券代码：688192 证券简称：迪哲医药 迪哲（江苏）医药股份有限公司 投资者关系活动记录表 （2023年12月12日） 投资者关系 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 活动类别 □新闻发布会 □路演活动 □现场参观 □一对一沟通 □其他（电话会议） 出席单位 2023年第三季度业绩说明会 及人员 时间 2023年12月12日15：00-16：00 地点 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http:// ...

证券代码：688192 证券简称：迪哲医药 迪哲（江苏）医药股份有限公司 投资者关系活动记录表 （2023年11月） 投资者关系 特定对象调研 分析师会议 □媒体采访 □业绩说明会 活动类别 □新闻发布会 □路演活动 □现场参观 一对一沟通 □其他（电话会议） 参与单位 天风医药 兴业医药 财通医药 东吴医药 中金医药 海通医药 华西医 及人员 药 新华基金 万家基金 华安基金 创金合信 中银基金 华宝基金 中 海基金 嘉实基金 东吴基金 天弘基金 华泰保兴 光正资管 财通自营 ...

单位：元 币种：人民币 重要内容提示： 一、 主要财务数据 注:"本报告期"指本季度初至本季度末 3 个月期间，下同。 2023 年第三季度报告 将《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益 项目界定为经常性损益项目的情况说明 □适用 √不适用 | --- | --- | --- | |----------------------------------------------|--------|-----------------------------------------------------------| | | | | | 基本每股收益（元 / 股） _ 年初 至报告期末 | 不适用 | | | 稀释每股收益（元 / 股） _ 本报 告期 | 不适用 | | | 稀释每股收益（元 / 股） _ 年初 至报告期末 | 不适用 | | | 加权平均净资产收益率（ % ） _ 本报告期 | 不适用 | | | 加权平均净资产收益率（ % ） _ 年初至报告期末 | 不适用 | | | 归属于上市公司股东的所有者 权益 _ 本报告期末 | -38.45 | 主要 ...

公司负责人：XIAOLIN ZHANG 主管会计工作负责人：吕洪斌 会计机构负责人：康晓静 103 / 171 2023 年半年度报告 三、 公司基本情况 1. 公司概况 √适用 □不适用 迪哲（江苏）医药股份有限公司系于2020 年9 月8 日由迪哲（江苏）医药有限公 司依法整体变更设立的股份有限公司，注册地为中华人民共和国江苏省无锡市。 根据中国证券监督管理委员会证监许可[2021]3494 号文《关于同意迪哲（江苏） 医药股份有限公司首次公开发行股票注册的批复》，本公司向境内投资者首次公开发 行40,000,100股人民币普通股A 股股票，并于2021年12月10日在上海证券交易所科创 板挂牌上市交易。 本公司及子公司（以下合称"本集团"）营业执照允许的经营范围包括：化学药品 制剂、化学药品原料药、生物药品的研发、批发；技术开发，技术转让，技术服务； 自营和代理各类商品及技术的进出口业务（国家限定企业经营或禁止进出口的商品和 技术除外）；经济与商务咨询（不含投资咨询）；许可项目：药品生产；药品批发； 药品零售（依法须经批准的项目，经相关部门批准后方可开展经营活动，具体经营项 目以审批结果为准）。 本财务 ...

2023 年第一季度报告 1 / 13 迪哲（江苏）医药股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 第一季度财务报表是否经审计 一、 主要财务数据 | --- | --- | --- | |-----------------------------------------------|-----------------|---------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期 \n增减变动幅度 (%) | | 营业收入 | - | 不适用 | | 归属于上市公司股东的净利润 | -239,523,659.32 | 不适用 | | 归属于上市公司股东的扣除非经 常性损益的净利润 | -250,734,331.87 | 不适用 | | 经营活动产生的现金流量净额 | -203,213,936 ...

Product Pipeline and Clinical Development - The company's product pipeline includes 5 products in global clinical development, with 2 products in global registration clinical trials, and 1 product in the process of market application[17] - Shuvotinib, a self-developed EGFR-TKI targeting EGFR Exon20 insertion mutations, achieved a confirmed tumor response rate (cORR) of 59.8%, with a cORR of 48.4% for patients with stable, asymptomatic brain metastases[22] - Golvatinib, a next-generation JAK1-specific inhibitor, has been granted "Fast Track Designation" by the US FDA and is undergoing registration clinical trials in China, the US, South Korea, and Australia[16] - DZD2269, a self-developed A2aR antagonist, showed dose-dependent efficacy in blocking adenosine/A2aR-mediated pathway activation in a Phase I trial, with no drug-related side effects observed at a 160mg dose[28] - DZD1516, a self-developed HER2 inhibitor, is designed to penetrate the blood-brain barrier and target HER2-positive breast cancer with CNS metastasis[13] - Golvatinib demonstrated significant efficacy in treating r/r PTCL, with 42.9% of patients achieving tumor response, including 22.4% complete response (CR) and 20.4% partial response (PR)[34] - DZD1516 showed a Kpuu,CSF ratio of 2.1, indicating complete penetration of the blood-brain barrier, and was well-tolerated at doses below 300 mg twice daily[43] - DZD8586 demonstrated promising preclinical results, effectively inhibiting the growth of B-cell non-Hodgkin lymphoma cells[42] - Sunvotinib received FDA Breakthrough Therapy Designation in January 2022[44] - Golvatinib received FDA Fast Track Designation for r/r PTCL in February 2022[53] - Sunvotinib's efficacy in EGFR Exon20ins NSCLC patients was presented at the 2022 ASCO and WCLC conferences[53] - DZD1516's Phase I clinical data for HER2-positive metastatic breast cancer was presented at the 2022 ESMO and SABCS conferences[53] - The leading product, Sunvozertinib, has reached the primary endpoint in its China registration clinical trial, and the new drug application has been accepted by the China National Medical Products Administration[116] - The company's main products, Suvotinib and Golixitinib, face uncertainty in obtaining conditional approval for market entry, with Suvotinib's application under priority review by the NMPA and Golixitinib under accelerated review by the FDA[169] Market and Commercialization Strategy - The company has established a globally competitive product pipeline and is building a commercial team in China to prepare for product launches[17] - The company is building a commercialization team in China and planning to establish independent production and R&D facilities[50] - The company plans to actively promote the inclusion of approved products in the national medical insurance catalog and explore innovative payment strategies to enhance product accessibility[58] - The company aims to expand market coverage and build a professional promotion team through continuous personnel training[58] - The company is focusing on market sales system construction and commercial production layout in 2022[72] - The company plans to adopt a combination of self-built teams and external cooperation for overseas market sales[86] - The company is actively seeking partners globally to promote the commercialization of core products[86] - The company is considering building its own sales team in key markets like the US to establish long-term global commercialization competitiveness[86] - The company's sales expenses were RMB 22,976,644.36, as the company prepared for product commercialization by building a sales team and market promotion[166] - The company's revenue and cost of sales were not applicable for the current period, as the company's products are still in the R&D phase and have not yet generated sales[166] R&D Strategy and Investment - The company focuses on clinical demand-driven drug development, conducting extensive research on clinical issues, future trends, and competitive product development[56] - The company tests and screens thousands to millions of compounds to identify lead compounds, optimizing them to select 2-3 candidate compounds with different characteristics[56] - The company prioritizes indications with potential for accelerated or conditional approval based on single-arm trial results to achieve rapid product commercialization[61] - The company's R&D strategy involves a comprehensive approach from protein to cell to animal and ultimately human trials to validate scientific hypotheses[56] - The company's clinical research is divided into Phase I, II, and III trials, with Phase III results being crucial for drug approval[61] - The company's R&D expenditure as a percentage of revenue was 5,712.89% in 2021, indicating a heavy focus on research and development[110] - The company's R&D expenses increased by 13.09% year-on-year to RMB 665 million, with rapid progress in research projects[116] - The company's R&D expenses for the reporting period amounted to 664.52 million yuan, reflecting significant investment in clinical and preclinical research[139] - The company's R&D expenses increased by 13.09% to RMB 664,521,836.83 due to ongoing investments in clinical trials and new product development[182] - The company's future performance may be impacted by ongoing large-scale R&D investments required for its product pipeline, including clinical trials and pre-market preparations[139] Financial Performance and Risks - Non-recurring gains and losses for 2022 include government subsidies of 6,385,137.00, primarily from government subsidy income[70] - The company's financial assets fair value change gains for 2022 amounted to 42,158,220.60, mainly from the fair value change gains of company's financial management[70] - The company's basic earnings per share for 2022 were -1.82 RMB, showing a slight improvement from -1.86 RMB in 2021[110] - The weighted average return on equity (ROE) for 2022 was -34.90%, a significant improvement from -86.44% in 2021[110] - Net profit attributable to shareholders in Q4 2022 was -225,905,869.78 RMB, the lowest among all quarters[112] - Net cash flow from operating activities in Q4 2022 was -181,921,939.10 RMB, showing a consistent negative trend throughout the year[112] - The company reported a net loss attributable to shareholders of 66.13 million yuan, an increase of 66.13 million yuan compared to the same period last year, primarily due to increased R&D expenses[147] - The company's foreign exchange gains amounted to 10.10 million yuan, driven by exchange rate fluctuations[140] - The company's financial expenses decreased by 212.39% to RMB -8,249,168.49, primarily due to foreign exchange gains from holding USD[182] - The company's management expenses increased by 19.91% to RMB 105,463,826.75, mainly due to increased administrative costs[182] - The company's net cash flow from operating activities was RMB -603,372,719.39, reflecting increased R&D expenditures[182] - The company's net cash flow from investing activities was RMB 384,556,016.08, driven by the maturity of large financial products[182] - The company's net cash flow from financing activities was RMB -33,264,923.37, mainly due to IPO issuance costs and rental payments[182] - The company's unprofitability is expected to continue, with cumulative losses likely to expand due to ongoing large-scale R&D investments[161] - The company's products are still in the clinical development stage and have not yet entered commercialization[189] Regulatory and Compliance - Shuvotinib's new drug application was accepted by the NMPA and included in the priority review and approval process in January 2023[22] - The company has obtained a "Drug Manufacturing License" (Bh) from the Jiangsu Provincial Drug Administration, ensuring the qualification for commercial production of its products[17] - The company has no major litigation or arbitration matters in the reporting period[102] - The company and its major shareholders have good integrity status[102] - The company's registered address was changed during the reporting period, moving to a new location in Wuxi[105] - The company maintains offices in both Wuxi and Shanghai, with postal codes 214135 and 201203 respectively[105] - The company's annual report is disclosed through major financial media outlets and the Shanghai Stock Exchange website[106] - The company's financial statements are audited by PricewaterhouseCoopers Zhong Tian LLP, with signing accountants Hu Wei and Guo Yike[109] - The company's sponsor for continuous supervision is CITIC Securities, with designated representatives Ding Yuan and Peng Liuyong[109] - The company renewed its appointment of PricewaterhouseCoopers Zhong Tian LLP (Special General Partnership) as its 2022 audit firm[190] - The company's 2022 annual report indicates no profit forecast or performance commitment was applicable[187] - The company's 2022 annual report was confirmed to be true, accurate, and complete by more than half of the directors[196] - The company's internal control audit was conducted by PricewaterhouseCoopers Zhong Tian LLP (Special General Partnership) with a fee of 450,000 RMB[190] - The company's domestic accounting firm remuneration for 2022 was 1.45 million RMB[190] Market and Industry Trends - HER2-positive breast cancer accounts for approximately 25% of all breast cancer cases, with CNS metastasis rates as high as 50% in HER2-positive patients[29] - PTCL accounts for 7%–10% of NHL globally, with a higher incidence rate of 25% in China compared to Western countries[25] - The global and Chinese NHL patient populations are projected to reach 670,000 and 117,000 by 2030, respectively[42] - Global new cancer cases increased from 17.64 million in 2017 to 19.74 million in 2021, with a compound annual growth rate of 2.8%[84] Risks and Challenges - The company faces significant market competition risks, particularly from large multinational corporations and domestic companies with stronger commercialization experience and resources[133] - The company faces risks from potential price increases in R&D technical services and materials, which could significantly impact operating costs[134] - The company's reliance on external financing for operational expenses poses a risk if funding is insufficient, potentially delaying or canceling R&D projects[137] - The company's equity incentive plans may lead to substantial share-based payment expenses, impacting future financial performance[138] - The company is exposed to risks from changes in drug pricing policies, including potential price reductions due to national medical insurance negotiations[142] - The company's international expansion may be affected by geopolitical and regulatory changes, impacting R&D and commercialization activities[155] - The company's leasing arrangements include a significant property lease in Shanghai with an annual rent and fixed property fee of 16.66 million yuan[151] - The company's trading financial assets decreased by RMB 416.18 million, from RMB 1.71 billion to RMB 1.29 billion, impacting the current profit by RMB 42.16 million[114] - The company's 2020 employee stock option plan requires incentive recipients to not sell shares for 36 months from the exercise date[184] Translational Science and Publications - DZD2269's translational science and pharmacodynamic biomarker research were published in the Journal of Experimental & Clinical Cancer Research (Impact Factor: 12.658)[46] Production and Supply Chain - The company has established standardized procurement processes, including end-to-end procurement procedures and supplier qualification management, to ensure efficient procurement of R&D services and materials[61] - The company's products are currently in the clinical trial stage and are produced through contract manufacturing organizations (CMO)[85]